Form 4: Hologic Merger Completes, Executive Stock Options Canceled

Hologic Inc. reports the completion of its merger, resulting in the cancellation of executive stock options and changes in beneficial ownership.

Summary

• Stacey D. Stewart, a Director at Hologic Inc., has reported changes in beneficial ownership of company stock.
• The transactions are related to the completion of a merger between Hologic, Inc. and Hopper Parent Inc. (through its subsidiary Hopper Merger Sub Inc.).
• As a result of the merger, Hologic common stock was converted into a right to receive $76.00 per share in cash, plus one contingent value right (CVR) per share, potentially worth up to an additional $3.00 in cash.
• All outstanding stock options held by the reporting person were canceled and converted into cash payments or CVRs, depending on their exercise price relative to the merger consideration.
• Following the merger, the reporting person no longer beneficially owns any shares of Hologic common stock directly or indirectly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports on the completion of a merger and the subsequent cancellation of executive stock options, rather than new operational or financial performance data.

Positives

• The merger consideration of $76.00 per share in cash provides immediate liquidity to shareholders.
• The inclusion of a contingent value right (CVR) offers potential for additional upside if certain conditions are met.

Negatives

• All outstanding stock options held by the reporting person were canceled, with some being converted into cash payments and others into CVRs, indicating a loss of potential future equity upside.
• The reporting person no longer beneficially owns any shares of Hologic common stock, which could signal a change in their direct financial stake in the company's future performance.

Risks

• The value of the CVR is contingent and may not be fully realized, representing a potential downside for shareholders.
• The cancellation of stock options means that the reporting person and potentially other executives will not benefit from future stock price appreciation above the exercise price.

Future Outlook

The future outlook for Hologic is now tied to the performance of the acquiring entity and the potential payout of the contingent value rights (CVRs). The reporting person's direct future financial benefit from Hologic's stock performance is eliminated.

Management Comments

• The merger agreement, dated October 21, 2025, outlines the terms of the acquisition by Hopper Parent Inc.
• Each share of Hologic common stock was converted into $76.00 in cash plus a contingent value right (CVR) for up to $3.00 in cash.
• Outstanding stock options were canceled and converted into cash or CVRs based on their exercise price relative to the merger consideration.

Industry Context

StockSavvy.ai notes that this Form 4 filing reflects a common outcome in acquisition scenarios where executive equity awards are cashed out or converted into deal consideration, signaling the end of Hologic's status as an independent publicly traded entity.

Stakeholder Impact

• Shareholders: Receive cash and potential CVR payout, ending their direct ownership in Hologic.
• Employees: May experience changes in reporting structure and benefits under new ownership.
• Management: Executive stock options are cashed out or converted, altering their direct financial incentives tied to Hologic's stock.

Next Steps

• Shareholders will receive the cash consideration and CVRs as per the merger agreement.
• The company will operate as a wholly owned subsidiary of Parent.
• The value of the CVRs will be determined by future performance metrics outlined in the merger agreement.

Key Dates

Keywords

Hologic Inc, HOLX, Form 4, Merger, Stock Options, Beneficial Ownership, SEC Filing, Contingent Value Right, Executive Compensation